The Human (HLA-DRA) Hla Class 2 Histocompatibility Antigen, Dr Alpha Chain ELISA Kit measures Hla Class 2 Histocompatibility Antigen, Dr Alpha Chain in samples. The plate has been pre-coated with Human HLA-DRA antibody. HLA-DRA present in the sample is added and binds to antibodies coated on the wells. And then biotinylated Human HLA-DRA Antibody is added and binds to HLA-DRA in the sample. Then Streptavidin-HRP is added and binds to the Biotinylated HLA-DRA antibody. After incubation unbound Streptavidin-HRP is washed away during a washing step. Substrate solution is then added and color develops in proportion to the amount of Human HLA-DRA. The reaction is terminated by addition of acidic stop solution and absorbance is measured at 450 nm.
Product Details
Species Reactivity
Human
Sensitivity
5.48 ng/L
Detection Range
10-2000 ng/L
Sample Type
Serum, plasma, cell culture supernates
Incubation(s)
1.5 hour(s)
Research Areas
Immunology, Immune molecule
Background
An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic Peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed: 29884618, PubMed: 17334368, PubMed: 81$458.00|$300.0019, PubMed: 15322540, PubMed: 22327072, PubMed: 27591323, PubMed: 31495665, PubMed: 15265931, PubMed: 9075930, PubMed: 24190431). Typically presents extracellular Peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed: 81$458.00|$300.0019). In the tumor microenvironment, presents antigenic Peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed: 31495665). Presents Peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed: 17182262, PubMed: 23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic Peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed: 25413013). The anchor residue at position 1 of the Peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed: 81$458.00|$300.0019). Source: UniProt Consortium (2025)
Shipping Condition
Shipped on cold gel packs.
Storage Condition and Shelf Life
2-8C
Analyte
Hla Class 2 Histocompatibility Antigen, Dr Alpha Chain
Regulatory Status
For Research Use Only
